Braidwell »

Cullinan Oncology shares owned by Braidwell

Quarter-by-quarter ownership of Cullinan Oncology (CGEM) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Cullinan Oncology

Tip: Access up to 7 years of quarterly data

All positions including Cullinan Oncology held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cullinan Oncology by Braidwell

Quarter filed Position value Share count Share price at filing
2023-12-31 $13M 1.2M 10.19
2023-09-30 $17M 1.9M 9.05
2023-06-30 $21M 1.9M 10.76

More positions owned by Braidwell

Guardant Health Note 11/1 (Principal)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Ascendis Pharma A/s Note 2.250% 4/0 (Principal)
Exact Sciences Corp Note 0.375% 3/0 (Principal)
Novocure Note 11/0 (Principal)
Neurocrine Biosciences (NBIX)
Vaxcyte (PCVX)
Xenon Pharmaceuticals (XENE)
Nuvasive Note 0.375% 3/1 (Principal)
Insulet Corp Note 0.375% 9/0 (Principal)
Tandem Diabetes Care Note 1.500% 5/0 (Principal)
Day One Biopharmaceuticals I (DAWN)
Irhythm Technologies (IRTC)
Argenx Se Sponsored Adr (ARGX)
Bridgebio Pharma Note 2.250% 2/0 (Principal)

View all positions for Braidwell

Top funds holding Cullinan Oncology

Blue Owl Capital Holdings
Franklin Resources
BVF
Vanguard Group
Braidwell
American International
Nextech Invest
Citadel Advisors
Dimensional Fund Advisors
Tang Capital Management
Deutsche Bank Aktiengesellschaft
OrbiMed Advisors
Charles Schwab Investment Management
Millennium Management
Hudson Bay Capital Management

View all funds holding Cullinan Oncology